Stock AFMD AFFIMED N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Affimed N.V.

Equities

AFMD

NL0015001ZQ0

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-05-03 EDT 		5-day change 1st Jan Change
5.42 USD +2.26% Intraday chart for Affimed N.V. +7.75% -13.28%
04-01 Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating MT
04-01 HC Wainwright Adjusts Affimed's Price Target to $10 From $50, Maintains Buy Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
AQ
Affimed Reports 2023 Financial Results and Operational Progress
AQ
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
AQ
Affimed N : Form 6-K
PU
Affimed Announces 1-for-10 Reverse Stock Split
AQ
AFFIMED ANNOUNCES LEADERSHIP CHANGE AND ORGANIZATIONAL RESTRUCTURING
AQ
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
GL
Affimed Announces Leadership Change and Organizational Restructuring
AQ
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
AQ
AFFIMED ANNOUNCES UPDATED PHASE DATA FROM ACIMTAMIG IN COMBINATION WITH ALLOGENEIC NK IN HODGKIN LYMPHOMA PATIENTS WHO FAILED PRIOR CHEMOTHERAPY AND ARE DOUBLE-REFRACTORY TO BRENTUXIMAB VEDOTIN AND CHECKPOINT INHIBITORS
AQ
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients
GL
Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)
GL
AFFIMED TO HOST INVESTOR CONFERENCE CALL HIGHLIGHTING CLINICAL DATA FOR ACIMTAMIG AND AFM24
AQ
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24
AQ
Affimed N : Form 6-K
PU
Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
AQ
Affimed Announces Acimtamig as International Nonproprietary Name for AFM13
AQ
Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023
AQ
Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
GL
Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AFMD Stock
  4. News Affimed N.V.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW